::: New startup out of University of Illinois, Vanquish Oncology, to Develop Personalized Therapeutics for Cancer Markets
University of Illinois, standalone cancer therapies, specific cancer cells, underserved cancer markets, lung cancer, liver cancer, colon cancer, breast cancer, cancer therapy, Vanquish Oncology focuses

::: U.S. Food And Drug Administration Approves Pfizer's INLYTA® (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
treatment of patients, individuals die of advanced RCC, effective following prior treatment options, Pfizer Oncology Business Unit, need of additional treatment options, First Treatment, Advanced Renal Cell Carcinoma, portfolio of treatment options, new treatment, prior systemic therapy based

::: FDA Approves BYDUREON(TM) -- The First and Only Once-Weekly Treatment for Type 2 Diabetes
patients taking once-weekly BYDUREON experienced, once-weekly diabetes treatment, patients taking BYDUREON, BYDUREON builds, BYDUREON uses Alkermes, first once-weekly treatment, Type 2 Diabetes, approval of BYDUREON, patients taking BYETTA, Glycemic Control

::: Pinpoint Genomics Announces Availability of its Pinpoint Dx Lung(TM) Assay
Pinpoint Dx Lung Assay, Pinpoint Genomics laboratory, Pinpoint Genomics logo, trademarks of Pinpoint Genomics, stage lung cancer, non-small cell lung cancer, multi-gene molecular diagnostic assay, development of the assay based, genomic-based clinical laboratory services

::: Bionovo to Voluntarily Delist from NASDAQ
NASDAQ Listing Rules, NASDAQ Capital Market, NASDAQ delisting process, NASDAQ stating, applicable NASDAQ rules, relevant NASDAQ rules, aforementioned NASDAQ letter, pharmaceutical company, company met, listing requirement